Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SOLX
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Details : SOLX is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 23, 2014
Lead Product(s) : SOLX
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : LifeBridge Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arixtra is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2013
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : LifeBridge Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Study Phase : Undisclosed
Recipient : Denver Health and Hospital Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Blood Coagulation Disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 22, 2012
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Recipient : Denver Health and Hospital Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
